Depo-Provera Lawsuit: Mass Tort Case Leads & Case Acquisition Intelligence

As of the October 1, 2026 JPML report, there are 6,412 pending actions in MDL-3140. As of CMO 12 (July 2026), state courts also had cases in Delaware (410), New York (129), California (118), Minnesota (72 cases with 6,899 plaintiffs), Connecticut (13 cases with 76 plaintiffs) and Illinois (12). Case count has grown over 8,100% since the MDL was created in February 2025.

New cases can still be filed, but under CMO 14 (August 10, 2026) the settlement's no-fee administrative docket is open only to eligible claimants who signed with a lawyer on or before June 11, 2026, and those claimants must register by November 30, 2026. People who sign with a lawyer after June 11 proceed as litigating plaintiffs, not settlement participants. Newly filed plaintiffs must send records-preservation notices within 60 days, serve case-specific expert reports within 90 days, mediate, and attend an in-person conference in Pensacola, and new filers diagnosed before March 27, 2024 must file a statute-of-limitations certification within 30 days. Filing has slowed sharply: pending cases rose by 9 in the October 2026 JPML report, down from 109 in September.

No settlement values have been disclosed. The parties signed a Master Settlement Agreement on July 21, 2026, but CMO 12 describes it as private and confidential. Pfizer's second-quarter 10-Q describes the terms as not material to the company's liquidity or financial condition and does not disclose an amount. We do not publish projected per-case values.

Depo-Provera was one of the fastest-growing MDLs, rising from 78 pending cases in March 2025 to 6,412 in the October 2026 JPML report (over 8,100% growth in 19 months). It remains smaller than mature MDLs like Talcum Powder (69K cases) or AFFF (15K cases). Growth has slowed sharply since the parties signed a Master Settlement Agreement on July 21, 2026: pending cases rose by 9 in the October 2026 report, down from 109 in September.

The first pilot trial (Toney v. Pfizer) had been set for December 7, 2026, with four more bellwethers to follow in January 2027. On June 15, 2026, after the parties reported a global settlement in principle, Judge Rodgers vacated the first bellwether trial and its pretrial deadlines, postponed the preemption ruling, and moved the general-causation (Daubert) hearing from June 24-25 to July 27, 2026. July 27 was held as the 12th case management conference instead, and CMO 12 set the general-causation hearing for September 18, 2026. CMO 12 also placed three new pilot cases (Yeager, Davis and Ponder) on a statute-of-limitations track, and CMO 14 stayed all other MDL proceedings.

Law firms can generate Depo-Provera lawsuit leads through several channels: organic SEO targeting lawsuit-related search terms, Google Ads for high-intent queries, Local Service Ads (LSAs) for Google-screened credibility, social media advertising on Facebook/Instagram targeting the plaintiff demographic, and dedicated niche websites built specifically for the Depo-Provera litigation. Firms investing in owned media assets (SEO, niche sites) often achieve better long-term unit economics than those relying solely on third-party lead sources.

The December 2025 FDA warning created significant search demand for Depo-Provera lawsuit information, and educational content can still reach people researching the litigation. But the litigation is no longer early-stage: the parties signed a Master Settlement Agreement on July 21, 2026, and pending cases rose by 9 in the October 2026 JPML report.

Dedicated niche sites for specific mass torts can outperform pages on a general law firm website. Benefits include: faster ranking for case-specific keywords, focused conversion optimization without competing firm priorities, cleaner attribution and analytics, and the ability to build topical authority quickly.

Google Ads captures high-intent searches from women actively researching the lawsuit. Local Service Ads (LSAs) provide Google-verified credibility and pay-per-lead pricing. Facebook/Instagram ads enable demographic targeting aligned with Depo-Provera users (women 25-55) and support video creative explaining the meningioma connection. Most successful firms use a multi-channel approach with proper attribution tracking to optimize spend allocation across channels.

For the settlement, the cutoff has passed. Under CMO 14 (August 10, 2026), the settlement's no-fee administrative docket is open only to eligible claimants who signed with a lawyer on or before June 11, 2026, and those claimants must register by November 30, 2026. People who sign with a lawyer after June 11 proceed as litigating plaintiffs, not settlement participants. Newly filed plaintiffs must send records-preservation notices within 60 days, serve case-specific expert reports within 90 days, mediate, and attend an in-person conference in Pensacola, and new filers diagnosed before March 27, 2024 must file a statute-of-limitations certification within 30 days.

Yes. Smaller firms can sign cases and refer to or co-counsel with established mass tort firms handling the litigation. This allows participation without the overhead of MDL leadership. Referral fees typically range from 25-40% of the originating firm's fee. Alternatively, firms can build their own inventory and join the MDL directly. Cases signed after June 11, 2026 proceed in litigation rather than through the settlement (CMO 14). Digital marketing (SEO, targeted ads) has leveled the playing field, allowing nimble firms to compete effectively against larger competitors.